The transaction was conducted on December 23, 2024, and was disclosed in a Form 4 filing with the Securities and Exchange Commission. Skorpios Trust, through its affiliated entities Blue Horizon Enterprise Ltd and Ezbon International Ltd, remains a significant stakeholder in the biotechnology firm. The shares are held indirectly, with Blue Horizon and Ezbon disclaiming beneficial ownership of each other's shares. The corporate trustee, Montrago Trustees Limited, also disclaims beneficial ownership except to the extent of its pecuniary interest. InvestingPro analysis indicates strong financial health with a current ratio of 5.09, while analyst price targets range from $15 to $35, suggesting potential upside from current levels. Subscribers can access 8 additional key insights about STOK's financial position and growth prospects. InvestingPro analysis indicates strong financial health with a current ratio of 5.09, while analyst price targets range from $15 to $35, suggesting potential upside from current levels. Subscribers can access 8 additional key insights about STOK's financial position and growth prospects.
The transaction was conducted on December 23, 2024, and was disclosed in a Form 4 filing with the Securities and Exchange Commission. Skorpios Trust, through its affiliated entities Blue Horizon Enterprise Ltd and Ezbon International Ltd, remains a significant stakeholder in the biotechnology firm. The shares are held indirectly, with Blue Horizon and Ezbon disclaiming beneficial ownership of each other's shares. The corporate trustee, Montrago Trustees Limited, also disclaims beneficial ownership except to the extent of its pecuniary interest.
In other recent news, Stoke Therapeutics (NASDAQ:STOK) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for its drug candidate zorevunersen. The drug is aimed at treating Dravet syndrome, a rare form of epilepsy. Positive outcomes from Phase 1/2a and open-label extension studies have shown that zorevunersen significantly reduced seizure frequency and improved cognitive and behavioral measures in patients. These are recent developments that have shaped Stoke Therapeutics' trajectory. The company is in ongoing discussions with the FDA and other global regulatory bodies to advance zorevunersen into a global, randomized, controlled Phase 3 registrational study. An update on the Phase 3 plans is expected by the end of the year. In other developments, TD Cowen has maintained its Buy rating for Stoke Therapeutics following the release of promising clinical trial results for zorevunersen. The company also settled a director compensation dispute, agreeing to a mootness fee of $175,000 and consenting to pay up to $415,000 in attorney's fees and expenses. This settlement includes the company's commitment to maintain specific director compensation policy changes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.